Trodelvy (sacituzumab govitecan-hziy)

No significant association was found between TROP2 expression and other histological parameters.ConclusionLoss of ≥50% nuclear 5-hmC is a sensitive and specific marker for distinguishing mesothelioma from RMH. High TROP2 expression in tumors with high mitotic figures and higher nuclear and tumor grade suggests these patients may benefit from sacituzumab govitecan therapy.

This study defines a new mechanism of barrier-mediated immune exclusion in cancer controlled by TROP2-dependent tight junctions. This mechanism drives tumor progression but can be targeted via TROP2-directed therapy to activate antitumor immunity and enhance immunotherapy response.

By contrast, sacituzumab govitecan is a TROP-2-targeted ADC conjugated through a hydrolysable CL2A linker to SN-38, the active metabolite of irinotecan. Clinically, trastuzumab deruxtecan has shown substantial efficacy in both HER2-positive and HER2-low breast cancer, whereas sacituzumab govitecan has demonstrated efficacy across triple-negative and hormone receptor-positive/HER2-negative breast cancers. Collectively, these agents highlight how variations in target antigen, linker chemistry, and payload potency impact ADC activity, therapeutic index, and potential strategies for sequential treatment in advanced breast cancer.

P1/2, N=30, Not yet recruiting, Medica Scientia Innovation Research S.L.

P2, N=87, Not yet recruiting, National Cancer Institute (NCI)

In conclusion, although SG is clinically effective for mTNBC, its high cost makes it economically unfeasible in mainland China. A substantial price reduction is essential for it to become a viable option, enabling more patients to benefit from its therapeutic potential.

In conclusion, SG showed similar effectiveness with ASCENT and TROPiCS-02 study in heavily pretreated Chinese MBC patients. Given the compromised effectiveness in patients with prior PD-1/PD-L1 inhibitors or PIK3CA mutation, future investigations are warranted to explore SG-based combination regimens or novel therapeutic strategies in the above population.

P2, N=32, Recruiting, The University of Texas Health Science Center at San Antonio | Trial completion date: Aug 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2027

P2, N=44, Completed, IRCCS San Raffaele | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Jun 2025 --> Sep 2025 | Recruiting --> Completed

Although the primary endpoint (ORR by IRC) was not met (P > .025), overall efficacy results were generally similar to TROPiCS-02, supporting access to SG in Japanese patients with HR+/HER2- mBC. Safety was consistent with the known and manageable SG safety profile.

P2, N=30, Not yet recruiting, West China Hospital

P1/2, N=120, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2027 --> Mar 2029 | Trial primary completion date: Mar 2026 --> Mar 2028